Probably not as your best option. If Wegovy was denied, compounded GLP-1s can be a fallback in some situations, but FDA-approved options are still preferred because compounded products are not FDA-approved and are not reviewed for safety, effectiveness, or quality before being marketed.[8][9] What matters most is why the denial happened and what access you still have: If Wegovy is denied because of insurance coverage, you may still be able to get an FDA-approved GLP-1 through: a prior authorization appeal a plan exception a different FDA-approved anti-obesity medication manufacturer savings programs, though these may be short-term[6] If you are looking at compounded semaglutide, it is not the same as Wegovy and is not a generic version; compounded products are custom-made by pharmacies and do not have the same evidence base as the branded drugs.[1] The FDA says compounded GLP-1s may be appropriate when a patient’s medical need cannot be met by an FDA-approved drug or the FDA-approved drug is not commercially available, but it also warns about fraudulent or mislabeled products.[8] A key practical issue: the large wave of compounded GLP-1 use was tied to prior shortages, but regulators have said major branded drugs like Wegovy are no longer in shortage, which has limited the rationale for routine compounding copies.[2][10] Bottom line: compounded GLP-1s are usually best viewed as a second-line access workaround, not the first choice. If you want the safest, most evidence-backed route, try to keep pushing for an FDA-approved option first, especially if you qualify medically.[1][8][9] If you want, I can help you compare: appealing the Wegovy denial switching to Zepbound, Saxenda, or other FDA-approved alternatives how to evaluate a compounder if you still decide to use compounded semaglutide
Mentioned in position 3 of 3
Read full answer with sources →